Compare Biocon Ltd with AJANTA PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

BIOCON vs AJANTA PHARMA - Comparison Results

BIOCON      Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    BIOCON AJANTA PHARMA BIOCON /
AJANTA PHARMA
 
P/E (TTM) x 22.6 22.2 101.7% View Chart
P/BV x 3.0 3.8 78.2% View Chart
Dividend Yield % 0.4 0.9 42.0%  

Financials

 BIOCON    AJANTA PHARMA
EQUITY SHARE DATA
    BIOCON
Mar-18
AJANTA PHARMA
Mar-19
BIOCON /
AJANTA PHARMA
5-Yr Chart
Click to enlarge
High Rs1,1881,422 83.6%   
Low Rs305898 34.0%   
Sales per share (Unadj.) Rs68.7233.5 29.4%  
Earnings per share (Unadj.) Rs7.644.0 17.2%  
Cash flow per share (Unadj.) Rs14.052.2 26.8%  
Dividends per share (Unadj.) Rs1.009.00 11.1%  
Dividend yield (eoy) %0.10.8 17.3%  
Book value per share (Unadj.) Rs86.3255.1 33.9%  
Shares outstanding (eoy) m600.0088.02 681.7%   
Bonus/Rights/Conversions ISBB-  
Price / Sales ratio x10.95.0 218.7%   
Avg P/E ratio x98.926.4 374.7%  
P/CF ratio (eoy) x53.422.2 240.3%  
Price / Book Value ratio x8.64.5 190.1%  
Dividend payout %13.220.5 64.7%   
Avg Mkt Cap Rs m447,900102,081 438.8%   
No. of employees `0006.16.8 90.4%   
Total wages/salary Rs m9,3114,307 216.2%   
Avg. sales/employee Rs Th6,705.83,022.6 221.9%   
Avg. wages/employee Rs Th1,514.2633.4 239.1%   
Avg. net profit/employee Rs Th736.9569.1 129.5%   
INCOME DATA
Net Sales Rs m41,23420,554 200.6%  
Other income Rs m2,062211 978.2%   
Total revenues Rs m43,29620,765 208.5%   
Gross profit Rs m8,2915,664 146.4%  
Depreciation Rs m3,851721 534.3%   
Interest Rs m61512 5,301.7%   
Profit before tax Rs m5,8875,143 114.5%   
Minority Interest Rs m2130-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,5691,273 123.3%   
Profit after tax Rs m4,5313,870 117.1%  
Gross profit margin %20.127.6 73.0%  
Effective tax rate %26.724.8 107.7%   
Net profit margin %11.018.8 58.4%  
BALANCE SHEET DATA
Current assets Rs m41,48611,812 351.2%   
Current liabilities Rs m21,4133,776 567.0%   
Net working cap to sales %48.739.1 124.5%  
Current ratio x1.93.1 61.9%  
Inventory Days Days6477 82.7%  
Debtors Days Days9482 115.4%  
Net fixed assets Rs m50,66114,398 351.9%   
Share capital Rs m3,000175 1,710.4%   
"Free" reserves Rs m48,80822,277 219.1%   
Net worth Rs m51,80822,452 230.7%   
Long term debt Rs m17,8987 271,181.8%   
Total assets Rs m99,89726,962 370.5%  
Interest coverage x10.6444.3 2.4%   
Debt to equity ratio x0.30 117,522.4%  
Sales to assets ratio x0.40.8 54.1%   
Return on assets %5.214.4 35.8%  
Return on equity %8.717.2 50.7%  
Return on capital %9.623.0 42.0%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m12,05810,682 112.9%   
Fx outflow Rs m7,3482,102 349.6%   
Net fx Rs m4,7108,580 54.9%   
CASH FLOW
From Operations Rs m6,6213,748 176.7%  
From Investments Rs m-6,840-2,228 307.0%  
From Financial Activity Rs m-2,397-1,475 162.6%  
Net Cashflow Rs m-2,61245 -5,778.8%  

Share Holding

Indian Promoters % 40.4 73.8 54.7%  
Foreign collaborators % 20.6 0.0 -  
Indian inst/Mut Fund % 8.4 1.6 541.9%  
FIIs % 10.7 7.6 140.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 19.9 17.0 117.1%  
Shareholders   109,995 20,968 524.6%  
Pledged promoter(s) holding % 0.0 4.4 0.9%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare BIOCON With:   TTK HEALTHCARE  ALEMBIC LTD  WYETH LTD  ELDER PHARMA  SUVEN LIFESCIENCES  

Compare BIOCON With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Continue Momentum; Sensex Trades 186 Points Higher(12:30 pm)

Share markets in India are presently trading on a strong note. Sectoral indices are trading on a mixed note with stocks in the telecom sector.

Related Views on News

AJANTA PHARMA Announces Quarterly Results (2QFY20); Net Profit Down 7.2% (Quarterly Result Update)

Nov 8, 2019 | Updated on Nov 8, 2019

For the quarter ended September 2019, AJANTA PHARMA has posted a net profit of Rs 1 bn (down 7.2% YoY). Sales on the other hand came in at Rs 6 bn (up 18.1% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

BIOCON Announces Quarterly Results (2QFY20); Net Profit Down 30.5% (Quarterly Result Update)

Nov 1, 2019 | Updated on Nov 1, 2019

For the quarter ended September 2019, BIOCON has posted a net profit of Rs 3 bn (down 30.5% YoY). Sales on the other hand came in at Rs 16 bn (up 19.0% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

AJANTA PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 8.4% (Quarterly Result Update)

Aug 2, 2019 | Updated on Aug 2, 2019

For the quarter ended June 2019, AJANTA PHARMA has posted a net profit of Rs 1 bn (up 8.4% YoY). Sales on the other hand came in at Rs 6 bn (up 19.8% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

BIOCON Announces Quarterly Results (1QFY20); Net Profit Down 11.5% (Quarterly Result Update)

Jul 29, 2019 | Updated on Jul 29, 2019

For the quarter ended June 2019, BIOCON has posted a net profit of Rs 1 bn (down 11.5% YoY). Sales on the other hand came in at Rs 5 bn (down 57.2% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

AJANTA PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Jun 24, 2019 | Updated on Jun 24, 2019

Here's an analysis of the annual report of AJANTA PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of AJANTA PHARMA. Also includes updates on the valuation of AJANTA PHARMA.

More Views on News

Most Popular

Crash Alert! Is There a Big Bubble in Nestle, HUL and Asian Paints?(Profit Hunter)

Nov 7, 2019

Is this the beginning of the end of multibagger gains in quality stocks like Nestle, HUL, and Asian Paints?

The Smartest Stock to Buy for 2020(Profit Hunter)

Nov 14, 2019

Small-cap stocks are selling at bargain prices today and are poised to generate a lot of wealth in 2020 and beyond...

Why Moody's Rating Downgrade is a Strong Sign to Buy Stocks(The 5 Minute Wrapup)

Nov 8, 2019

Investors who took cues from Moody's rating downgrade in 1992 and 2002 created some of the biggest wealth of their lifetime.

A Trade that Could Generate Profits for Decades

Nov 14, 2019

India's #1 trader is back on the Investor Hour. Vijay Bhambwani talks to us about his super-profitable trading system and shares with us his #1 long term trade. Listen in...

The One Trade I'm Most Bullish on Now

Nov 12, 2019

A highly specific trade to potentially triple your money in just three months. You won't find this information anywhere else!

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

BIOCON SHARE PRICE


Nov 19, 2019 03:31 PM

TRACK BIOCON

BIOCON - TTK HEALTHCARE COMPARISON

COMPARE BIOCON WITH

MARKET STATS